AKCA Akcea Therapeutics Inc.

23.72
+0.24  (+1%)
Previous Close 23.48
Open 23.52
Price To Book 5.66
Market Cap 2,200,513,817
Shares 92,770,397
Volume 16,227
Short Ratio
Av. Daily Volume 209,831

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx
Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus
Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 2 data presented at AHA November 2018 - endpoints met.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 3 data due mid-2019.
Volanesorsen
Familial partial lipodystrophy (FPL)
Phase 1/2 data and Phase 3 trial initiation due 2H 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis

Latest News

  1. hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
  2. Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
  3. Investors Who Bought Akcea Therapeutics (NASDAQ:AKCA) Shares A Year Ago Are Now Down 13%
  4. Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
  5. Akcea Therapeutics to Present at Upcoming Investor Conferences
  6. Ionis Pharmaceuticals Is 40% of the Way There
  7. Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Call Transcript
  8. Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates
  9. Akcea Therapeutics: 1Q Earnings Snapshot
  10. Akcea Reports Financial Results and Highlights for First Quarter 2019
  11. Can Pfizer Leap Over the Competition With This Potential Blockbuster?
  12. New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
  13. Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
  14. Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
  15. Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?
  16. Here’s What Hedge Funds Think About Akcea Therapeutics, Inc. (AKCA)
  17. Akcea Therapeutics (AKCA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
  18. Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
  19. Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
  20. Why Akcea Therapeutics, Inc. (NASDAQ:AKCA) Is A Financially Healthy Company